Cargando…

Liquid biomarkers in melanoma: detection and discovery

A vast array of tumor-derived genetic, proteomic and cellular components are constantly released into the circulation of cancer patients. These molecules including circulating tumor DNA and RNA, proteins, tumor and immune cells are emerging as convenient and accurate liquid biomarkers of cancer. Cir...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Su Yin, Lee, Jenny H., Diefenbach, Russell J., Kefford, Richard F., Rizos, Helen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5772714/ https://www.ncbi.nlm.nih.gov/pubmed/29343260 http://dx.doi.org/10.1186/s12943-018-0757-5

Ejemplares similares

Methylated circulating tumor DNA as a biomarker in cutaneous melanoma
por: Diefenbach, Russell J, et al.
Publicado: (2020)

Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients
por: Lim, Su Yin, et al.
Publicado: (2017)

Interferon Signaling Is Frequently Downregulated in Melanoma
por: Alavi, Sara, et al.
Publicado: (2018)

Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2020)

Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms
por: Lim, Su Yin, et al.
Publicado: (2018)

p16(INK4a)-induced senescence is disabled by melanoma-associated mutations
por: Haferkamp, Sebastian, et al.
Publicado: (2008)

Analysis of the Whole-Exome Sequencing of Tumor and Circulating Tumor DNA in Metastatic Melanoma
por: Diefenbach, Russell J., et al.
Publicado: (2019)

Genetic Alterations in the INK4a/ARF Locus: Effects on Melanoma Development and Progression
por: Ming, Zizhen, et al.
Publicado: (2020)

Oncolytic virotherapy using herpes simplex virus: how far have we come?
por: Sokolowski, Nicolas AS, et al.
Publicado: (2015)

Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
por: Shklovskaya, Elena, et al.
Publicado: (2020)

Oncogenic PI3K/AKT promotes the step-wise evolution of combination BRAF/MEK inhibitor resistance in melanoma
por: Irvine, Mal, et al.
Publicado: (2018)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Circulating Tumor DNA Reflects Uveal Melanoma Responses to Protein Kinase C Inhibition
por: Park, John J., et al.
Publicado: (2021)

Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition
por: Lee, Jenny H., et al.
Publicado: (2020)

Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
por: Park, John J., et al.
Publicado: (2022)

Targeted BRAF Inhibition Impacts Survival in Melanoma Patients with High Levels of Wnt/β-Catenin Signaling
por: Chien, Andy J., et al.
Publicado: (2014)

Melanoma Cell State-Specific Responses to TNFα
por: Lim, Su Yin, et al.
Publicado: (2021)

The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16(INK4a)
por: Becker, Therese M, et al.
Publicado: (2009)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

Proteomics in Melanoma Biomarker Discovery: Great Potential, Many Obstacles
por: Sabel, Michael S., et al.
Publicado: (2011)

The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma
por: Lim, Su Yin, et al.
Publicado: (2023)

Multiomic Approaches for Cancer Biomarker Discovery in Liquid Biopsies: Advances and Challenges
por: Diaz, Paola Monterroso, et al.
Publicado: (2023)

Evaluation of stromal HGF immunoreactivity as a biomarker for melanoma response to RAF inhibitors
por: Lezcano, Cecilia, et al.
Publicado: (2014)

Targeting BRAF for patients with melanoma
por: Arkenau, H-T, et al.
Publicado: (2011)

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence
por: Haferkamp, Sebastian, et al.
Publicado: (2009)

Towards precision medicine: advances in 5-hydroxymethylcytosine cancer biomarker discovery in liquid biopsy
por: Zeng, Chang, et al.
Publicado: (2019)

Multiplex detection of ctDNA mutations in plasma of colorectal cancer patients by PCR/SERS assay
por: Lyu, Nana, et al.
Publicado: (2020)

Oncogenic B-RAF(V600E) signaling induces the T-box3 transcriptional repressor to repress E-cadherin and enhance melanoma cell invasion
por: Boyd, Suzanah C., et al.
Publicado: (2012)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

Resistance to c-Kit inhibitors in melanoma: insights for future therapies
por: Carlino, Matteo S., et al.
Publicado: (2014)

The Potential of Omics Technologies in Lyme Disease Biomarker Discovery and Early Detection
por: Badawi, Alaa
Publicado: (2016)

Current Trends in Circulating Biomarkers for Melanoma Detection
por: Huang, Nancy, et al.
Publicado: (2022)

Discovery of KIRREL as a biomarker for prognostic stratification of patients with thin melanoma
por: Lundgren, Sebastian, et al.
Publicado: (2019)

Liquid biopsy for esophageal cancer: Is detection of circulating cell‐free DNA as a biomarker feasible?
por: Yuan, Zuyang, et al.
Publicado: (2020)

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma
por: Gray, Elin S., et al.
Publicado: (2015)

Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
por: Shklovskaya, Elena, et al.
Publicado: (2022)

Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma
por: Krückel, Annika, et al.
Publicado: (2019)

Application of Holistic Liquid Chromatography-High Resolution Mass Spectrometry Based Urinary Metabolomics for Prostate Cancer Detection and Biomarker Discovery
por: Zhang, Tong, et al.
Publicado: (2013)

Advances in Cardiovascular Biomarker Discovery
por: Ghantous, Crystal M., et al.
Publicado: (2020)

The application of Aptamer in biomarker discovery
por: Li, Yongshu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5q2b0aism3mj52iqqrpu7bdle3